Ortho Clinical Diagnostics K.K.

Ortho Clinical Diagnostics K.K., a Japanese subsidiary of Ortho Clinical Diagnostics, supplies VITROS chemistry and immunoassay analyzer testing reagents, consumables, and related laboratory diagnostic equipment to the U.S. Department of Defense as a prime contractor operating 100% of its federal award footprint on a full-and-open, non-set-aside basis. The vendor competes exclusively against full competition with no socioeconomic set-aside participation across its federal portfolio.

The vendor's federal customer base concentrates almost entirely on military health operations in the Indo-Pacific region. The Department of the Navy Bureau of Medicine and Surgery dominates by order count (218 awards, $13.1 million combined potential value), while the Defense Health Agency leads by dollar value (34 awards, $14.9 million), and the Department of the Air Force Pacific Air Forces represents the third tier (33 awards, $8.6 million). These three customers account for 99% of awards across the footprint. The concentration reflects the vendor's role as the established primary supplier of VITROS laboratory reagents and consumable supplies to naval hospitals in Yokosuka, Atsugi, Sasebo, and Iwakuni, as well as air force bases including Misawa and Yokota in Japan. A single recompete exposure of $4.9 million arrives within the next twenty-four months.

Ortho Clinical Diagnostics K.K. holds multiple active indefinite-delivery vehicles with the Defense Health Agency and Navy Bureau of Medicine and Surgery. The Defense Health Agency operates two single-award blanket purchase agreements: a $2.875 million BPA (effective July 1, 2024 through June 30, 2029) for VITROS 7600 laboratory testing equipment consumables at Yokota Air Base and other military medical facilities throughout Japan, against which 106 task orders totaling approximately $3.3 million have been issued; and a $250,000 BPA (October 1, 2025 through September 30, 2030) for laboratory medical supplies supporting the Medical Department Activity in Japan. The Navy Bureau of Medicine and Surgery holds indefinite-delivery contracts valued at $1.54 million (expired September 2023) and supplementary vehicles supporting ongoing delivery orders for VITROS reagents across naval hospitals and research centers. Pacific Air Forces operates a decentralized BPA for laboratory supplies at Misawa Air Base. The vendor also holds a $4.853 million sole-source purchase order (May 2023 through September 2027) for VITROS XT7600 reagents and consumables at U.S. Naval Hospital Yokosuka. Recent award activity shows annual fluctuation—35 awards in 2022, declining to one in 2024, then recovering to 21 in 2025 and eight in 2026 through April—reflecting task-order deployment patterns against standing indefinite-delivery vehicles rather than new vehicle competition. All work is performed in Japan on firm fixed-price terms.

The vendor's capability portfolio is narrowly specialized: in-vitro diagnostic substance manufacturing dominates the NAICS distribution (229 awards), with analytical laboratory instrument manufacturing (33 awards) and surgical and medical instrument manufacturing (29 awards) as minor components. Primary Service Classification (PSC) coding aligns, with in-vitro diagnostic substances, reagents, test kits, and sets representing 167 awards and medical and surgical instruments, equipment, and supplies accounting for 73 awards. Concrete recent work includes BPA calls from the Defense Health Agency for VITROS chemistry and immunoassay analyzer testing reagents and consumables in the $833 to $69,442 range, delivery orders from the Navy Bureau of Medicine and Surgery for VITROS laboratory reagents to support naval hospitals and research centers (ranging from $1,155 to $203,712), and a $105,199 sole-source purchase order from the Defense Health Agency (December 2023 through December 2028) for preventive maintenance and repair of Ortho Immunohematology Analyzers at U.S. Naval Hospital Okinawa. The vendor has operated as the primary supplier of VITROS laboratory diagnostic materials to the Defense Health Agency and Navy Bureau of Medicine and Surgery since 2021, with cumulative potential value across all active vehicles exceeding $7.2 million.